AnaPath Research pubblication part 1
AnaPath Research pubblication part 2
Immunohistochemical detection of p53 and pp53 Ser392 in canine hemangiomas and hemangiosarcomas located in the skin
AnaPath 2020 new Company Introduction is available!
Please view below or contact us for your own pdf version.
AnaPath Services acquires Envigo CRS S.A.U. in Barcelona to provide full
services in non-clinical safety assessment for chemical and pharmaceutical industries English.
NEWS PROVIDED BY
AnaPath Services GmbH
Nov 21, 2019, 04:32 ET
GENEVA, Nov. 21, 2019 /PRNewswire/ — AnaPath Services GmbH, the Swiss CRO specialized in histopathology, has acquired legacy Envigo CRS S.A.U. a CRO for non-clinical safety assessment on November 5th , 2019.
With this step Envigo CRS was renamed to AnaPath Research S.A.U.
Furthermore Jorge Zapatero Lorenzo was appointed the general manager of AnaPath Research. Mr Zapatero has been with the company from 1986 until 2014 in roles of increasing responsibility including general manager. This merger represents a back integration as both companies worked previously together within RCC / Harlan Laboratories Spain and Switzerland. After separating due to a buyer of Harlan in 2013, AnaPath developed into a globally recognized expert CRO in histopathology and toxicology.
Common history, personal relationship and shared values will make a quick start and integration as one CRO possible; after implementation of technical upgrades, GLP in vivo studies start January 2020. This merger enhances AnaPath’s capabilities and warranties a quick and clean performance of complete safety assessment packages under one roof. The basis for this statement is given by thorough knowledge about each others skills, previously joint training periods, and organization and performance of study packages. AnaPath Services is well known for its high level scientic approach serving clients with strategies and solutions to overcome developmental hurdles. The merger enables AnaPath to convert its understanding of toxicology into immediate progression of critical milestones within Research & Development.
SOURCE AnaPath Services GmbH
December 2019: Klaus′ latest publications is online
A series of regulatory studies were carried out to investigate the effects of the FAAH inhibitor BIA 10–2474 on fertility, embryo-fetal toxicity and pre- and post-natal development in rats and rabbits. Despite some reductions in sperm count in rats from 50 mg/kg, there were no major changes in male fertility up to 100 mg/kg. In female rats administered up to GD6, there were increases in pre-implantation loss at 50 and 100 mg/kg but neither post-implantation loss nor early embryonic development was affected. In contrast, when administered to female rats during pregnancy (GD6-GD17), BIA 10–2474 at 75 mg/kg/day reduced food consumption resulting in weight loss, increased post-implantation loss and reduced mean fetal body weight. In rabbits, the same maternal toxicity was seen but there were no effects in this species on post-implantation loss or fetal body weights. There were no teratological effects clearly due to BIA 10–2474 and developmental milestones and behavior of offspring were not affected. When administered during pregnancy and lactation (GD6-PND20), some post-implantation loss was seen from 20 mg/kg/day, but developmental milestones and behavior of the offspring were not affected, although males tended to have lower body weight. Based on these data the NOAEL for parental fertility was established as 50 mg/kg/day, the maternal NOAEL during pregnancy was 25 mg/kg/day in rats and developmental NOAEL was 25 and 75 mg/kg/day in rats and rabbits, respectively. When administered during post-natal development to rats the maternal NOAEL was 6 mg/kg/day. The parental reproductive NOAEL, the NOAEL for viability and growth of the F1 offspring, the F1 parental NOAEL and the F1 reproductive NOAEL were all considered to be 20 mg/kg/day.
BIA 10-2474 is a novel fatty acid amide hydrolase (FAAH) inhibitor developed for the treatment of medical conditions which would benefit from enhanced levels of endogenous anandamide (AEA) such as pain disorders. During a Phase I clinical trial one subject died after receiving BIA 10-2474 and four other subjects displayed neurological signs. As part of series of papers presenting all the toxicology data available prior to the clinical trial, we report here the preclinical toxicology studies examining once-a-day oral administration of BIA 10-2474 to male and female Wistar rats. These included a 14-day dose range finding (150, 200 and 250 mg/kg/day), a 4-week study (30, 90 and 150 mg/kg/day) and 13- and 26-week studies (both at 10, 30 and 90 mg/kg/day). The 13- and 26-week studies also included a 4-week recovery arm and a toxicokinetic arm for the parent compound, BIA 10-2474, and the two major metabolites (BIA 10-2445 and BIA 10-2583) were also measured in the 26-week study. At 150 mg/kg and below, all animals survived the scheduled treatment periods although neurological side-effects (abnormal or stiff gait, dragging of fore- or hind-limbs) were seen at 150 mg/kg in both the dose-range finding and 4-week studies. At 90 mg/kg/day, even up to 26-weeks treatment, no clinical signs were seen apart from some decreases in body weight gain. A number of consistent hematological and biochemical changes were noted which were considered related to treatment with BIA 10-2474. Morphologically, in the 4-week study, except for a slight gliosis in the hippocampus of one female at 150 mg/kg, no CNS histopathology was observed; hippocampus gliosis was not observed in subsequent studies. In the 13-week study axonal swelling was present in the medulla oblongata in about half the animals at 90 mg/kg/day and this increased to nearly all the rats at 90 mg/kg/day in the 26-week study. Additional signs seen only in the 26-week study at 90 mg/kg/day included axonal swelling of the fasiculus gracilis and vacuolar changes in the medulla oblongata and ventral commissure of the 3rd ventricle. Other findings included vacuolar degeneration in the ganglia of the GI tract, salivary glands, prostate gland, uterus, and parathyroid glands. The pituitary gland showed edema and mitotic figures in the pars nervosa. These observations outside the CNS were seen in most rats at 90 and 150 mg/kg/day independent of study duration. At 30 mg/kg/day, most of these observations were only seen in isolated cases except for the vacuolar degeneration in GI tract ganglia, which was absent at this dose after 4 weeks treatment but was present in almost all rats at 13 and 26 weeks. Hepatocellular hypertrophy and nephropathy were seen across all studies and the extent of these changes was similar in the 13- and 26-week studies. Most findings resolved after the 4-week recovery periods except for the axonal swelling seen in the medulla oblongata and spinal cord. BIA 10-2474 exposure was markedly higher than the exposure to either metabolite, BIA 10-2445 (19- to 192-fold) and BIA 10-2583 (63- to 526-fold). Exposure to metabolites differed between sexes with higher concentrations of BIA 10-2445 in females compared to males, but the inverse for BIA 10-2583. Although a No Observed Adverse Effect Level (NOAEL) of 30 mg/kg/day was concluded following the 4-week study, the histopathological findings at that dose in the 13- and 26-week studies resulted in the NOAEL being determined to be 10 mg/kg/day.
August 2019: Klaus′ latest publication is online
Pardo, I.; WEBER, K.; Cramer, S.; Krinke, G.; Butt, M.; Sharma, A. and Bolon, B.: Atlas of Normal Microanatomy, Procedural and Processing Artifacts, Common Background Findings, and Neurotoxic Lesions in the Peripheral Nervous System of Laboratory Animals. Toxicol Pathol (2019).
August 2019: We are hiring a Junior BD/Proposal Manager!
Click on the link to find a detailed job description: Junior- Business Development Manager, Proposal Manager, Marketing and Administrative Support in Commercial Services
July 2019: We offer qPCR analysis!
AnaPath is offering real-time PCR (qPCR) analysis using CE/IVD-certified instruments, thus adding molecular biology amongst the long list of expertise of the company.
June 2019: Eurostars grants project funding for personalized ovarian cancer therapy selection – 3D SELECT
A total grant sum of EUR 3.47 million has been awarded to a multidisciplinary project, named ‘3D SELECT’. The European consortium consist of six collaborating partners: VitroScan, Anapath, FHNW, Uppsala University, Oncodia, and Robovision. The project uniquely combines expertise in 3D culturing, pathology, genomics, proteomics and AI to accelerate the development of the 3D-SELECT platform to analyse drug response on small tumour biopsies from individual patients and identify most efficacious treatment.
May 2019: We are hiring!
Practical IT and GLP Computerized System Specialist: https://anapath.ch/job-openings/
March 2019: We train apprentices!
medi has officially accredited us as apprenticing company.
November 2018: The publication on synthetic amorphous silica is online now!
Read the publication here: Publication on SAGE Journals
November 2018: We are hiring again! / Wir verstärken unser Team erneut!
Toxicologic Pathologist, Technician for Necropsies and Histotechnique
November 2018: Nils Krüger and Klaus Weber on Synthetic Amorphous Silica
September 2018: Come Listen to our Talks !
Dr. Klaus Weber will present a series of two talks on October 3 rd , 2018
Where: Technologiepark, Hochbergerstrasse 60C, CH-4057 Basel
Room – Charivary – 7 th floor
When: October 3 rd , 2018
15.00 – 18.00 pm
Role of the Study Pathologist (15.00 in English)
For all individuals who are interested in pathology, the impact of pathology in development and safety assessment and those who plan a study involving pathology readouts. Variables Affecting the Interpretation of
Toxicology Studies (16.30 in German)
For all individuals who are involved in the design, conduct and evaluation of in vivo/tox studies.
January 2018: New GLP Certificate Available
The new AnaPath GLP Certificate is available at the Quality Assurance page !
December 2017: New Webpage
AnaPath launches new webpage! Take time and have a look at the new content and design!
October 2016: Japanese Society of Toxicologic Pathology (JSTP)
The AnaPath GmbH is proud to announce and welcome a new board-certified pathologist in the team:
Klaus Weber, Toxicologic Pathologist, D.V.M, PhD, DJSTP
Yes, Klaus, co-founder of AnaPath GmbH, took the challenge and recently qualified as the 498th board-certified diplomate of the Japanese Society of Toxicologic Pathology (JSTP).
The society has been dealing with the promotion of the scientific field of toxicologic pathology (by annual scientific meetings and publication of the Journal of Toxicologic Pathology), the quality certification of trained toxicologic pathologists (by the board certification system; Diplomate of JSTP) and the continuous education as well as training of not only young fellows but also diplomates (by annual slide conferences and annual education seminars).
February 2016: 3D Laser Scanning Confocal Microscopy
AnaPath GmbH continuous to advance into the future by integrating advanced interdisciplinary scientific techniques into histopathology. 3D Laser Scanning Confocal Microscopy is the next generation non-contact measuring solution. In the hands of our experience d staff it offers a wide range of possibilities for accurate analyses. We can offer analyses of e.g. blood, sperm and BALF smears, bone and implant surfaces, microspheres, encapsulated polymers, matrix, scaffolds and much more. Please get in touch with us today to discuss how we can support your research: firstname.lastname@example.org
January 2016: Expanding Capabilities in Bio-Implant Testing
AnaPath GmbH is strengthen its capabilities in bio-implant testing through a collaboration with the RMS Foundation.
The RMS Foundation is certified according to SN EN ISO 9001, accredited according to ISO/IEC 17025 and highly competent in testing medical and material technology. RMS broad test portfolio includes individual testing services for materials, implants and medical products: incoming inspection of raw materials, chemical analytics and microstructure investigations, electron microscopy, static and dynamic testing of specimens and products, surface and cleanliness analysis and failure reports. Through discussion customized test designs for e.g. implant stability can be conducted.
Please get in touch with us today to discuss how we can support you.
For more information visit: www.rms-foundation.ch
December 2015: Laser Capture Microdissection
AnaPath GmbH extends the molecular pathology services into Laser Capture Microdissection. Laser Capture Microdissection (LCM) is an automated sample preparation technique that enables isolation of tissue regions or specific cells from a mixed population under microscopic visualization. At AnaPath we use tissue samples as frozen or FFPE samples for microdissection and can conduct LCM under GLP. Please get in touch with us today to discuss how we can support your research.